According to the report, the size of the Europe Nucleic Acid Isolation and Purification Market is valued at USD 0.90 billion in 2022. It is estimated to be growing at a CAGR of 7.58% and will worth USD 1.30 billion by 2027. Europe is anticipated to register substantial growth in the global NAIP market during the forecast period. This regional market is strongly supported by the cognizance of DNA and RNA, economic strength to purchase costly tools, and acceptable reimbursement schemes that propel the region's market growth. The escalating insistence for a clear form of nucleic acid for drug delivery and burgeoning improvements in clinical diagnostics techniques impels the growth in the nucleic acid isolation and purification market. Moreover, the existence of different novel applications like molecular diagnostic testing, expression analysis, and genotyping may create chances for providers in the region.
Rising utilization of NAIP and growing support from the European governments towards the R & D are primarily supporting the market in this region. The price pertaining to genetic sequencing lessons, the latest technologies for the enhancements of genetics, and the consumption of personalized medicine and diagnostics are the factors propelling the market growth in the region. Moreover, the reinforcement of novel drugs, mergers and acquisitions, and the launch of new products and collaborations made bolstered the development of the nucleic acid isolation and purification market in Europe. Enlargement of next-generation sequencing (NGS) technologies as DNA and RNA play a vital role in acquiring exact NGS data is thriving the region's market growth. Bolstering the frequency of genetic disorders and increasing laboratory automation and reducing irregularity may propel the nucleic acid isolation and purification market.
Less ratification of self-acting nucleic acid isolation and purification procedures is a factor hampering the growth. The cost associated with the devices used in the purification and isolation of nucleic acid is one key factor obstructing the market's growth. Lack of experienced professionals and rising market amalgamation are hindering the market growth over the period.
This research report on the Europe Nucleic Acid Isolation and Purification Market has been segmented and sub-segmented into the following categories:
Based on region, the market in this region is projected to grow strongly during the forecast period due to various factors such as growing awareness about DNA and RNA, financial strength to procure expensive tools, and favorable reimbursement policies.
The United Kingdom NAIP market is leading the European market with the largest share due to the pharmaceutical companies' surging investments, growing research and development out-goings, and escalating automation are flourishing the growth. Quick technology advancements such as PCR have moved clinical microbiologists' approach over the usage of nucleic acid techniques, and the rising number of biotechnology industries are some factors boosting the market growth in Europe.
France and Germany are expected to have considerable growth in the upcoming years due to increasing patient safety concerns. The capability to be photocopied and exact results are some prominent aspects of laboratory efficacy. The growing insistence for the production industry assisting in improving nucleic acid-based products like DNA vaccine and double-stranded RNA non-coding molecules is swelling the growth of the nucleic acid isolation and purification market.
Prominent Companies leading the Europe Nucleic acid isolation and purification market Profiled in the Report are Qiagen, Bio-Rad Laboratories Inc, Illumina Inc, Agilent Technologies Inc, Thermo Fischer Scientific Inc, F. Hoffmann-La Roche AG, Sigma-Aldrich Co. LLC, General Electric Company, Danaher Corporation, Promega Corporation, Life Technologies, Roche Applied Sciences, Takara Bio, Inc., etc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org